Posts Tagged ‘breast cancer’

Join Us For a Live Webcast on Friday, June 22

Posted by • June 14th, 2012

The NEJM 200th anniversary symposium, Dialogues in Medicine: Physicians and Patients on 200 Years of Progress, is only a week away!  You are all invited to participate in one or all four sessions via live webcast on Friday, June 22 from 9 AM to 5 PM Eastern time.  Get a group together to hear our… Read More…

Vote for the Most Important Article, 1980-1989

Posted by • June 1st, 2012

For the most important advance during the early years of NEJM, you voted for the beginning of ether anesthesia. From 1880-1929, it was the first description of platelets, and from 1930-1959, the beginning of bone marrow transplantation. The 1960s brought us studies on an attenuated measles vaccine, and the first oral ACE inhibitor was introduced… Read More…

HER2-Positive Breast Cancer

Posted by • May 25th, 2012

In the latest Case Record of the Massachusetts General Hospital, a 32-year-old woman noted a crease in her right breast. Imaging studies showed a suspicious mass, and a biopsy specimen revealed infiltrating ductal carcinoma, positive for HER2. Staging showed liver lesions consistent with metastases. Management decisions were made. HER2, a proto-oncogene encoding the HER2 tyrosine kinase… Read More…

Bevacizumab in Breast Cancer

Posted by • January 26th, 2012

In a new study from von Minckwitz et al, bevacizumab added to neoadjuvant combination chemotherapy increased the rate of pathological complete response among patients with HER-2-negative early-stage breast cancer. The effect was greatest in patients with the poorest prognosis, those with so-called triple-negative tumors. The efficacy of neoadjuvant chemotherapy, as measured by the rate of pathological complete… Read More…

Rethinking Breast Cancer and Bevacizumab

Posted by • January 25th, 2012

The Food and Drug Administration (FDA) recently revoked its approval of the agent bevacizumab (also known as Avastin), a monoclonal antibody against vascular endothelial growth factor A, for treating metastatic breast cancer. Did they act too fast? According to Von Minckwitz et al., bevacizumab, when added to neoadjuvant chemotherapy, may offer considerable benefits for patients with… Read More…

Breast Cancer

Posted by • October 5th, 2011

In a study from Slamon et al., trastuzumab added to a nonanthracycline regimen to treat HER2-positive breast cancer resulted in rates of disease-free and overall survival that were similar to those for an anthracycline-containing regimen, with lower rates of cardiac toxicity and secondary leukemia. The HER2 gene encodes a tyrosine kinase receptor that mediates critical signaling… Read More…

Breast-Cancer Screening

Posted by • September 16th, 2011

The latest article in our Clinical Practice series reviews current recommendations for breast-cancer screening and thesupporting evidence, including the controversy regarding mammographic screening of women in their 40s. Worldwide, breast cancer is now the most common cancer diagnosed in women and is the leading cause of deaths from cancer among women, with approximately 1.3 million… Read More…

Inflammatory Breast Cancer

Posted by • June 10th, 2011

In this week’s Case Record of the Massachusetts General Hospital, a 49-year-old woman presented with a 12-cm mass in the right breast, fixed to the chest wall. The overlying skin was erythematous and edematous. A core-biopsy specimen showed infiltrating ductal carcinoma. Of all breast cancers, only 1 to 6% are classified as inflammatory breast cancer. Approximately… Read More…